Antengene Corporation Limited (6996) AI Stock Analysis

• Market Cap: HK$1.99B
• Dividend Yield: N/A
• Average Volume (3M): 5.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: 30.54%
• EPS Growth: 46.26%
• Country: HK
• Employees: 169
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.27
• Shares Outstanding: 679,446,660
• 10 Day Avg. Volume: 5,349,164
• 30 Day Avg. Volume: 5,326,493
• PEG Ratio: 0.61
• Price to Book (P/B): 1.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$2.08
• Price Target Upside: -33.73% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: ―

Antengene Corporation Limited's stock score is impacted by strong revenue growth but weighed down by substantial profitability and cash flow issues. The balance sheet offers some stability with low leverage. Technical indicators provide a mixed signal with long-term momentum but short-term caution. The valuation reflects high risk due to negative earnings and lack of dividends.

Antengene Corporation Limited Business Overview & Revenue Model

Company Description

Antengene Corporation Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for the treatment of cancer, infectious diseases, and other life-threatening disorders. The company primarily operates in the pharmaceutical and biotechnology sectors and is headquartered in China. Antengene's core products include a pipeline of proprietary and partnered drug candidates at various stages of development, aimed at addressing unmet medical needs in oncology and related therapeutic areas.

How the Company Makes Money

Antengene Corporation Limited generates revenue primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is based on sales of its proprietary drugs, licensing agreements, and strategic partnerships. Antengene collaborates with global pharmaceutical and biotechnology companies to co-develop products, share research and development costs, and gain access to advanced technologies and markets. Additionally, the company may receive milestone payments and royalties from its partners as part of licensing agreements. These partnerships and collaborations contribute significantly to its earnings by expanding its product portfolio and market reach.

Antengene Corporation Limited Financial Statement Overview

Summary

Antengene Corporation Limited shows strong revenue growth but faces significant profitability and cash flow challenges. The balance sheet remains relatively stable with low leverage, providing some buffer against ongoing losses. Immediate attention to operational and cash flow management is essential to enhance financial health and sustain future growth.

Income Statement

The company shows consistent revenue growth over the years, with a notable increase from 2023 to 2024. However, the profitability metrics are concerning as both EBIT and Net Income margins are significantly negative, indicating ongoing operational losses. The gross profit margin is relatively strong at approximately 80.65% in 2024, but the high negative net income margin of -347.28% suggests severe challenges in managing expenses relative to revenue.

Balance Sheet

The balance sheet presents a strong equity position with a high equity ratio of 63.28% in 2024, reflecting a solid asset base funded by equity rather than debt. The debt-to-equity ratio is low at 0.29, indicating limited leverage. However, the continuous high net losses have eroded stockholders' equity over time, posing a risk to financial stability.

Cash Flow

Cash flow figures indicate significant challenges, with consistently negative operating and free cash flows. The operating cash flow to net income ratio is undefined due to zero operating cash flow in 2024, highlighting inefficiencies in converting revenue to cash. The free cash flow has improved from a negative base, but remains a critical area of concern.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
91.95M	67.31M	160.13M	28.77M	0.00
	Gross Profit
74.17M	55.01M	132.00M	24.19M	0.00
	EBIT
-364.74M	-691.45M	-878.93M	-618.24M	-502.33M
	EBITDA
-348.82M	-550.31M	-866.06M	-614.32M	-501.94M
	Net Income Common Stockholders
-319.25M	-581.18M	-601.49M	-655.53M	-2.93B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
900.24M	1.19B	1.79B	2.37B	3.11B
	Total Assets
1.34B	1.62B	2.14B	2.56B	3.19B
	Total Debt
249.44M	201.02M	57.95M	14.81M	10.92M
	Net Debt
-650.70M	-461.31M	-1.73B	-2.26B	-3.10B
	Total Liabilities
493.93M	471.20M	428.84M	163.29M	156.59M
	Stockholders Equity
850.80M	1.15B	1.71B	2.39B	3.04B
Cash Flow		Free Cash Flow
0.00	-778.87M	-665.56M	-581.04M	-358.87M
	Operating Cash Flow
0.00	-665.77M	-572.18M	-557.65M	-307.12M
	Investing Cash Flow
0.00	587.07M	-208.16M	-103.88M	-600.57M
	Financing Cash Flow
0.00	131.84M	-20.73M	-81.29M	2.79B

Antengene Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.14
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6996, the sentiment is Neutral. The current price of 3.14 is below the 20-day moving average (MA) of 3.83, below the 50-day MA of 3.33, and above the 200-day MA of 1.77, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.95 is Neutral, neither overbought nor oversold. The STOCH value of 5.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6996.

Antengene Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1093	76 Outperform	$87.63B	19.06	13.20%	2.62%	-9.60%	-27.18%
2269	74 Outperform	$98.06B	27.18	8.17%	―	7.52%	-1.92%
1513	74 Outperform	$32.28B	11.57	14.56%	4.18%	-5.37%	6.28%
1177	66 Neutral	$89.24B	47.03	6.14%	12.58%	7.63%	-24.23%
1873	58 Neutral	HK$3.28B	18.36	4.47%	―	-9.75%	―
Sector *	53 Neutral	$5.22B	3.33	-44.36%	7.55%	16.78%	-0.12%
6996	46 Neutral	HK$1.99B	―	-31.66%	―	30.54%	46.26%

Antengene Corporation Limited Corporate Events

Antengene Corporation Announces 2025 AGM with Key Resolutions

Antengene Corporation Limited has announced its upcoming annual general meeting (AGM) to be held on June 13, 2025, both online and physically in Shanghai, China. The AGM will address several key resolutions, including the approval of the company’s financial statements for 2024, the re-election of directors, the re-appointment of Ernst & Young as auditors, and the authorization for directors to manage share allotments. These resolutions are crucial for Antengene’s governance and operational strategies, potentially impacting its market positioning and stakeholder relationships.

Antengene Announces Share Repurchase Plan to Boost Shareholder Value

Antengene Corporation Limited has announced its intention to conduct an on-market share repurchase, utilizing a mandate approved by shareholders to buy back up to 10% of its issued shares. This move, subject to market conditions, is aimed at demonstrating confidence in the company’s business outlook and enhancing shareholder value, with the repurchase financed by internal resources.

Antengene Reports Revenue Growth and Reduced Losses for 2024

Antengene Corporation Limited reported a 36.7% increase in revenue for the year ended December 31, 2024, driven by strong sales in Mainland China, despite a price reduction following the inclusion of XPOVIO® in the National Reimbursement Drug List. The company also achieved substantial cost reductions across research and development, selling and distribution, and administrative expenses, resulting in a decreased annual loss of RMB319.3 million, compared to RMB581.2 million in the previous year. This financial performance highlights Antengene’s improved operational efficiency and strategic market positioning.

Antengene Corporation to Review Annual Financial Results

Antengene Corporation Limited has announced that its board of directors will meet on March 21, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024. This meeting is significant as it will impact the company’s financial reporting and provide insights into its performance, potentially influencing investor and stakeholder perspectives.

Antengene’s XPOVIO® Gains Approval in Indonesia for Multiple Indications

Antengene Corporation Limited announced that the Indonesia National Agency of Drug and Food Control has approved the New Drug Application for XPOVIO® (selinexor) for three specific indications, including treatments for multiple myeloma and diffuse large B-cell lymphoma. This approval marks a significant milestone for Antengene, enhancing its market presence in the Asia Pacific region and potentially improving treatment options for patients with these conditions.

Antengene Expands AI Investment to Boost T-Cell Engager Development

Antengene Corporation Limited announced plans to expand its investment in artificial intelligence by establishing a dedicated AI department, which will enhance its drug discovery efforts. This strategic move aims to accelerate the development of its T-cell engager pipeline, positioning the company as a pioneer in AI-powered drug discovery and strengthening its competitive edge in the biotechnology industry.

Antengene’s XPOVIO Gains Taiwan Health Insurance Approval

Antengene Corporation Limited announced that its drug XPOVIO (selinexor), in combination with bortezomib and dexamethasone, has been approved for reimbursement in Taiwan’s National Health Insurance scheme starting March 1, 2025. This approval marks a significant milestone for Antengene, potentially boosting its market presence in Taiwan and enhancing its competitive positioning in the biopharmaceutical industry, particularly in the treatment of relapsed/refractory multiple myeloma.